Table 1.
Patient and tumor characteristics*
| Characteristics | Value (n = 96) |
|---|---|
| Age, median (IQR), y | 60.5 (55–71.2) |
| Height, median (IQR), cm | 161 (156.8–164.7) |
| Weight, median (IQR), kg | 67 (57.7–75.4) |
| BMI, median (IQR), kg/m2 | 25.6 (22.6–28.9) |
| Menopausal status, No. (%) | |
| Pre/Peri | 9 (9.4) |
| Post | 87 (90.6) |
| ER/PR status, No. (%) | |
| Positive | 84 (87.5) |
| Negative | 12 (12.5) |
| HER2 status, No. (%) | |
| Positive | 15 (15.6) |
| Negative | 79 (82.3) |
| Unknown | 2 (2.1) |
| Subtype, No. (%) | |
| HR+ and HER2- | 69 (71.9) |
| HER2+ and any HR | 15 (15.6) |
| Triple-negative | 10 (10.4) |
| Unknown | 2 (2.1) |
| Grade, No. (%) | |
| Grade I | 9 (9.4) |
| Grade II | 44 (45.8) |
| Grade III | 34 (35.4) |
| Unknown | 9 (9.4) |
| Line of treatment starting, No. (%) | |
| 1 | 34 (35.5) |
| 2 | 25 (26.0) |
| 3+ | 37 (38.5) |
| Type of treatment to be initiated, No. (%) | |
| Chemotherapy | 53 (55.2) |
| Anti-HER2 agent + chemotherapy | 2 (2.1) |
| Only anti-HER2 agent | 6 (6.2) |
| Hormone therapy | 33 (34.4) |
| Unknown | 2 (2.1) |
| Lung metastases, No. (%) | |
| Yes | 42 (43.8) |
| No | 54 (56.3) |
| Liver metastases, No. (%) | |
| Yes | 39 (40.6) |
| No | 57 (59.4) |
| Brain metastases, No. (%) | |
| Yes | 6 (6.3) |
| No | 90 (93.7) |
| Bone metastases, No. (%) | |
| Yes | 76 (79.2) |
| No | 20 (20.8) |
*
ER = estrogen receptor; HER2 = human epidermal growth factor receptor 2; HR = hormone receptor; IQR = interquartile range; PR = progesterone receptor.